Menopause and sexuality: key issues in premature menopause and beyond

Graziottin, Alessandra

doi:10.1111/j.1749-6632.2010.05680.x

Cited by 45 publications

(32 citation statements)

References 32 publications

(158 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…75 Signs and symptoms of estrogen deficiency include vaginal thinning, dryness, loss of elasticity, as well as difficulty with sexual arousal, interest, and sexual pain. 76 In a study of women undergoing risk reducing BSO, oophorectomized women reported significantly more vaginal dryness and dyspareunia than did the control group, despite the use of HT after surgery, suggesting that changes in sexual functioning are sustained and not entirely reversed by HT following BSO.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Long-term health consequences of premature or early menopause and considerations for management

et al. 2015

View full text Add to dashboard Cite

Aim To review the current evidence concerning the long-term harmful effects of premature or early menopause, and to discuss some of the clinical implications. Material and methods Narrative review of the literature. Results Women undergoing premature or early menopause, either following bilateral salpingo-oophorectomy or because of primary ovarian insufficiency, experience the early loss of estrogen and other ovarian hormones. The long-term consequences of premature or early menopause include adverse effects on cognition, mood, cardiovascular, bone, and sexual health, as well as an increased risk of early mortality. The use of hormone therapy has been shown to lessen some, although not all of these risks. Therefore, multiple medical societies recommend providing hormone therapy at least until the natural age of menopause. It is important to individualize hormone therapy for women with early estrogen deficiency, and higher dosages may be needed to approximate physiological concentrations found in premenopausal women. It is also important to address the psychological impact of early menopause and to review the options for fertility and the potential need for contraception, if the ovaries are intact. Conclusions Women who undergo premature or early menopause should receive individualized hormone therapy and counseling.

show abstract

Section: Resultsmentioning

confidence: 99%

“…77 Sexual dysfunction in women with early BSO is often multifactorial, related not just to the physiologic consequences of hormonal deprivation, but also to psychological aspects. 74, 75 …”

Section: Resultsmentioning

confidence: 99%

Long-term health consequences of premature or early menopause and considerations for management

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Cuando la libido es el problema, la Tibolona o los andrógenos transdérmicos ayudan mucho. Aunque, los problemas sexuales ameritan un abordaje psico-bio-sociosexual bajo contextos de cambios físicos, intrapersonales, interpersonales y sociales (30,31).…”

Section: Síntomas Genitourinarios Y Sexualesunclassified

Menopausia: panorama actual de manejo

Pérez

Rojas

2011

Rev. Med.

View full text Add to dashboard Cite

rev. fac. med.56 19 (1): 56-65, 2011 Resumen Aún existe, desde 2002, una marcada disminución en el uso de terapia hormonal clásica (TH), para el manejo de la menopausia, debido a los riesgos determinados en el estudio Iniciativa de salud para las mujeres (WHI: Women's Health Initiative). No obstante, revisiones del WHI y evidencias actuales determinan que la TH: (a) es la terapia más efectiva de los síntomas vasomotores, de sus potenciales consecuencias (disminución en calidad del sueño, irritabilidad, reducción en calidad de vida), y para tratar la atrofia urogenital. (b) Previene la osteoporosis y en pacientes con endotelios sanos, reduce el riesgo de hipertensión arterial, diabetes II y enfermedad coronaria, siendo el cociente beneficio/ riesgo mayor cuando se inicia tempranamente al sucederse el hipoestrogenismo. (c) Existe la tendencia a utilizar dosis mínimas, estrógenos no orales y progestágenos puros, para disminuir sus riesgos. (d) Tibolona y paroxetina son las mejores alternativas para tratar los síntomas vasomotores. (e) Finalmente, los cambios a estilo de vida saludable son coadyuvantes excelentes de la TH en el manejo de los síntomas menopaúsicos y en la prevención de las enfermedades crónicas de la postmenopausia, las cuales ameritan tratamientos específicos. Menopause: an overview of current assessment and management AbstractThere has been a marked decline in hormonal therapy (HT) for menopausal symptoms, since 2002, due the understanding of the benefits and risks as described in the Women's Health Initiative (WHI). Nevertheless, revisions of the WHI and current evidences determine that the HT: (a) is the most effective treatment for menopause vasomotor symptoms and their potential consequences (diminished sleep quality, irritability, and reduced quality of life), and to treat urogenital atrophy. (b) prevents the osteoporosis and, in women with healthy endothelial arteries, it reduces the risk of hypertension, diabetes II and coronary heart disease; but, the benefit-risk ratio is favorable for women who initiate HT close to ovarian failure or menopause. (c) There is the tendency to minimize dose, give no oral estrogens and pure progestagens, in order to diminish its potential risks. (d) Tibolona and Paroxetine are good alternatives to treat menopausal vasomotor symptoms. (e) Finally, the changes in the lifestyle are excellent HT adittional aids to prevent postmenopausal chronic diseases; but these diseases deserve specific treatments.

show abstract

“…). In patients with HL, sexual function is associated with POF (Schover , Graziottin , Millheiser et al . , Sturdee & Pines ) and psychological distress and changes in role and social functioning (Hordern , Roper et al .…”

Section: Introductionmentioning

confidence: 99%